ProCE Banner Activity

RIGHT Choice: Subgroup Analyses From the Phase II Trial of First-line Ribociclib + ET vs Combination Chemotherapy in Clinically Aggressive HR+/HER2- Advanced Breast Cancer

Conference Coverage
Slideset

This subgroup analysis from the phase II RIGHT Choice study of ribociclib plus endocrine therapy (ET) vs combination chemotherapy suggests there is predictive value of intrinsic subtypes and immune-related gene expression levels for the benefit of ribociclib + ET in patients with clinically aggressive HR+/HER2- advanced breast cancer.

Released: December 18, 2024

Expiration: June 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation